Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

BACKGROUND: Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a benefit of combining olaparib with immunotherapy in prostate cancer patients bo...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Immunother Cancer
Main Authors: Fenerty, Kathleen E., Padget, Michelle, Wolfson, Benjamin, Gameiro, Sofia R., Su, Zhen, Lee, John H., Rabizadeh, Shahrooz, Soon-Shiong, Patrick, Hodge, James W.
格式: Artigo
語言:Inglês
出版: BioMed Central 2018
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6264611/
https://ncbi.nlm.nih.gov/pubmed/30486888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0445-4
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍